capebretongirl wrote: I'm not sure what it will take to snag that great future. This has been very disappointing over the past few months - not that long ago at $1.57 folks were talking about the moon and $10 -$50 shareprices for starters - after all, known positive Q results were just about to be announced (covid rev) along with a 20 year tech called Aristotle - how could the sp not climb from there? Since the roll out and CARE planned acquisition along with its dillution, that wild and elated speculation has peeled back to calls of the most optimistic for the likes of $1.25 -1.50 - I haven't seen anyone speculate even $5.00 over the past months - this is indeed the shift in reality of today given our .475 and dropping sp, not to mention warrants having fallen from a high of .11 to .025.
On April 1 investors were shocked when they were asked to sideline their dreams for Aristotle as a stand alone purchase, in favor of embracing CARE's AVRT program as the way of the future. Aristotle has now been out there for 3 months in an abreiviated AVRT form but aside from the company's largely social media, occasional Investor Tel and TV Business slot marketing, main stream media outlets have not promoted the technology on a holy grail basis. We look forward to Shift helping out as Aristotle is still not a pop up on any Google search for liquid biopsy cancer testing. Sorry to say, but this is where we are today.
Cancer revenue is the flavour of the day with covid drying up - Q2 won't likely be much (cancer rev) as I expect unpaid promotional tests were a mainstay. Q3 will reflect the ramp up with CARE and only then will we get a glimpse of what the future holds. Q4 will be announced in early 2022 and that will give the best insight. Clarus deep sixed this with its revised $1.25 downgrade which has clearly resulted in the exit of Institutional buyers - thus our low low daily volume. A revisit by Atkinson with an upgraded sp would be invaluable right now for investor confidence, however I don't know if any effort is being made on that front.
As for an R/S 2-1, I see the argument on both sides - however I would not be disappointed if the concensus is NO. This and any company having completed a recent 8-1 is undeserving of further manipulation simply to see a .95 sp pop up on our screens. SZ needs to show investors that it can EARN cancer revenue, grow the sp to a reasonable level and perhaps then consider a 2-1 based on merit, if it would get us to the NAS threshold at that time. Truth is that if we do a 2-1 now and the sp drops back, another R/S would likely be implemented under the same rationale.
I still hold out hope for a breakthrough with a large employer, insurer, or affiliate to light the fire under this as the technology is so promising - this was always the dream pre CARE. Clearly however, there has been resistance on all those fronts and without such a development we will go the longer route with CARE and AVPT in order to assess the future success of this company.
RelevantStock wrote: The company itself Stagezero is promised to a great future - they have chosen the best technology 20 years ago with mRNA. This board is a mess though, especially since Aristotle out the game pumpers / bashers play is clear and we cannot have any normal discussion anymore. It's clearer now to me that people here have roles and it takes away the fun I had to chat and read here haha.
When there is a long sideways phase like this one there is most the time a breakout at the end. I'm still holding a large number of shares but my hopes are not for the short term anymore, but still anything can happen.
I dont know how much it cost for that spot on BNN tv, but the result in terms of value added on the stock price is quite disappointing.
SAGDollar wrote: Glad I got out of this dumpster fire. Broke 1000% today in mmat. Called it a loss when Noel snickered and hung up in the conference call. Glad I sold at 1.07.